Analysts show less optimism post-results due to lowered revenue forecasts and minor EPS downgrade. Despite growth acceleration, China Resources Double-Crane PharmaceuticalLtd is predicted to lag behind industry average. Concerns arise as EPS estimates are reduced, indicating potential business challenges.

Despite a recent boost in China Resources Double-Crane Pharmaceutical's stock, its low P/E ratio suggests investors expect limited future growth. The company's forecast growth is lower than the wider market, indicating a potential lack of strong share price rise in the near future.

The company's five-year earnings growth track record has boosted its market reputation. Despite modest recent returns, the five-year total shareholder return is impressive at 13% per year. The stock's peak may have passed, or the price may be stabilizing as the business continues to perform.

Investors foresee restrained growth for China Resources Double-Crane PharmaceuticalLtd, which may be affecting its P/E ratio. Current circumstances could obstruct a substantial share price rise.

Despite recent stock price drop, the company's long-term prospects seem positive with steady EPS growth and a TSR surpassing share price. The recent sell-off could be a potential opportunity if long-term growth trends persist.